Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

Usha Chakravarthy, Simon P Harding, Chris A Rogers, Susan M Downes, Andrew J Lotery, Lucy A Culliford, Barnaby C Reeves, on behalf of the IVAN study investigators

Research output: Contribution to journalArticle (Academic Journal)peer-review

Abstract

Bevacizumab has been suggested to have similar effectiveness to ranibizumab for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial was designed to compare these drugs and different regimens. Here, we report the findings at the prespecified 2-year timepoint.
Original languageEnglish
Pages (from-to)1258-1267
JournalLancet
Volume382
Issue number9900
Early online date19 Jul 2013
DOIs
Publication statusPublished - 12 Oct 2013

Bibliographical note

Copyright © 2013 Chakravarthy et al. Open Access article distributed under the terms of CC BY-NC-SA. Published by Elsevier Ltd. All rights reserved.

Structured keywords

  • BTC (Bristol Trials Centre)
  • Centre for Surgical Research

Fingerprint Dive into the research topics of 'Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial'. Together they form a unique fingerprint.

Cite this